Datapoint: AstraZeneca, Daiichi Score Earlier Breast Cancer Use for Enhertu

The FDA on May 5 approved AstraZeneca and Daiichi Sankyo’s Enhertu for earlier use in metastatic, HER2+ breast cancer patients. The antibody treatment is currently approved as a third-line therapy, and can now be used as a second-line therapy in patients with recurring disease within six months of receiving a different HER2 inhibitor. As a breast cancer therapy, Enhertu currently holds covered or better status for 63% of all insured lives under the pharmacy benefit. Under the medical benefit, the drug holds 78% covered or better status.

SOURCE: MMIT Analytics, as of 5/11/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 1

Datapoint: FDA Approves Lilly’s Jaypirca in Blood Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 31

Datapoint: Independence Blue Cross to Launch Advanced Network for Gene Therapies

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today